ArticleRheumatology (Oxford, England)2025
Risk of venous thromboembolism in people with RA: a population-based study in the UK.
Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The risk of venous thromboembolism in RA.Rheumatology (Oxford, England) · 2026Review
- Exploring the risk of venous thromboembolism in women with rheumatoid arthritis initiating menopausal hormone treatment in England.Rheumatology advances in practice · 2026Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
objectivesTo evaluate the absolute and relative risk of venous thromboembolism (VTE) in individuals with RA, with relation to age, sex, BMI, disease duration and exposure to exogenous oestrogens.
methodsIndividuals with RA, registered with the UK Oxford-RCGP RSC primary care database between 1999 and 2018, were matched 1:4 with individuals without RA. Multivariable-adjusted Cox proportional hazards was used to compare VTE risk, stratified by age, sex, BMI, disease duration and prescription of oestrogen-containing contraceptives or hormone replacement therapy (HRT).
resultsVTE risk was higher in individuals with RA (n = 23 410) than the matched controls (n = 93 640): adjusted hazard ratio 1.46 (95% CI 1.36, 1.56). Absolute risk of VTE increased with age and higher BMI. Compared with the controls, however, the relative excess risk of VTE was higher in younger than older individuals: 18-49 years (2.13; 95% CI 1.62, 2.79); 50-69 years (1.57; 95% CI 1.38, 1.78); ≥70 years (1.34; 95% CI 1.14, 1.60) and higher in individuals with normal vs elevated BMI: <25 kg/m2 (1.66; 95% CI 1.39, 1.98); 25-30 kg/m2 (1.60; 95% CI 1.36, 1.88); >30 kg/m2 (1.41; 95% CI 1.19, 1.68). VTE risk remained elevated irrespective of disease duration, was similar between women prescribed vs not prescribed oestrogen-containing contraceptives and higher for women prescribed HRT than those not prescribed HRT.
conclusionIndividuals with RA are at increased risk of VTE regardless of age, sex, BMI, disease duration and exposure to exogenous oestrogens. This highlights the need to consider VTE risk in all individuals with RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.